To compare the risk of major bleeding in patients with non-valvular atrial fibrillation initiating oral antocagulants(Apixaban,Dabigatran,Rivaroxaban or Warfarin)

Trial Profile

To compare the risk of major bleeding in patients with non-valvular atrial fibrillation initiating oral antocagulants(Apixaban,Dabigatran,Rivaroxaban or Warfarin)

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2017 New trial record
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top